Clearside Biomedical enrolls first patient in Ph3 macular edema trial

This article was originally published here

Clearside Biomedical (NSDQ:CLSD) has enrolled the first patient in a Phase III trial evaluating its eye drug combined with an intravitreally-administered anti-VEGF agent as a treatment for macular edema associated with retinal vein occlusion.

The company’s drug, CLS-TA, is a proprietary suspension of triamcinolone acetonide designed to be administered in the space located between the choroid and the sclera.

Get the full story at our sister site, Drug Delivery Business News.

The post Clearside Biomedical enrolls first patient in Ph3 macular edema trial appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply